Full Press Release Details
Accessibility: Skip TopNav
Summit Therapeutics plc : Holding(s) in Company
February 20, 2015 08:28 ET
Summit Therapeutics plc
Summit Therapeutics plc
| TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i | ||
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | SUMMIT THERAPEUTICS PLC | |
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||
| An acquisition or disposal of voting rights | X | |
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||
| An event changing the breakdown of voting rights | ||
| Other (please specify): | ||
| 3. Full name of person(s) subject to the notification obligation: iii | Polar Capital LLP | |
| 4. Full name of shareholder(s) (if different from 3.): iv | ||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | 19.02.2015 | |
| 6. Date on which issuer notified: | 20.02.2015 | |
| 7. Threshold(s) that is/are crossed or reached: vi, vii | >3% |
| 8. Notified details: | |||||||
| A: Voting rights attached to shares viii, ix | |||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||
| GB00BN40HZ01 | 1,233,066 | 1,233,066 | 1,303,066 | 1,303,066 | 3.17% | ||
| B: Qualifying Financial Instruments | |||||||
| Resulting situation after the triggering transaction | |||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||
| N/A | |||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||
| Resulting situation after the triggering transaction | |||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | ||
| N/A | Nominal | Delta | |||||
| Total (A+B+C) | |||||||
| Number of voting rights | Percentage of voting rights | ||||||
| 1,303,066 | 3.17% |
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | |
| Proxy Voting: | |
| 10. Name of the proxy holder: | |
| 11. Number of voting rights proxy holder will cease to hold: | |
| 12. Date on which proxy holder will cease to hold voting rights: | |
| 13. Additional information: | |
| 14. Contact name: | Polar Capital Operations Department |
| 15. Contact telephone number: | +44 (0) 207 227 2700 |